ZURICH (Reuters) - Lonza said on Tuesday the first patient has been treated with a cell therapy made in its "Cocoon" platform, which the Swiss contract drug maker hopes catches on at medical centers ...

Under the terms of the collaboration, Leucid will utilise Lonza as its preferred manufacturer, aiming to deliver high quality cell therapies quickly and cost-effectively to patients in a decentralized ...

Lonza and Sheba Medical Center have successfully dosed four patients with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon automated manufacturing platform. On Aug. 12, 2021, Lonza and Sheba ...

LEIDEN, Netherlands, June 23, 2021 /PRNewswire/ -- CellPoint, a cell therapy company developing CAR-T therapeutics for use at the point-of-care, announces an agreement with Lonza's Personalized ...

Lonza’s CocoonTM manufacturing platform will be used by Israel’s largest hospital, Sheba Medical Center at Tel Hashomer, to develop point-of-care cell-therapy manufacturing. Cocoon has been designed ...

Lonza agreed to a collaboration that will integrate Agilent’s current and new analytics technologies and techniques into the Lonza Cocoon ® platform’s cell therapy manufacturing workflow to explore ...

BASEL, Switzerland & MONTRÉAL & AUSTIN, Texas--(BUSINESS WIRE)--Lonza and Triumvira Immunologics ("Triumvira") announced that the first patient has been dosed with Triumvira's investigational T-cell ...

Lonza plans to ensure consistent product quality by incorporating Agilent’s analytics technology into its Cocoon platform. Lonza and Agilent announced a strategic collaboration to incorporate new ...